PharmaEssentia's Ropeg Wins Essential Thrombocythemia Approvals in US and Asia
PharmaEssentia says Ropeg received approvals for essential thrombocythemia in the US and Asia.
Related stories
Knife River Reports Q3 EPS of $2.43, Trims 2026 Revenue Guidance
Third-quarter revenue was $1.28 billion. EPS and revenue were below FactSet estimates of $2.60 and $1.30 billion, respectively; 2026 revenue guidance is $3.38 billion to $3.43 bill
M impact | EQUITY | Nov 03, 2026, 02:35 PM UTC
Utkarsh Small Finance Bank Reports Q2 Net Loss of 698.5 Million Rupees
M impact | EQUITY | Nov 03, 2026, 02:35 PM UTC
Apple shares fall after Ternus warns of memory costs
Apple shares fell after Ternus warned about memory costs.
L impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
Clorox Shares Rise About 6% After Q1 Results Beat
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
TransAlta shares rise 7.7% as net earnings turn positive
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
IPG Photonics Reports Third-Quarter 2026 Revenue of $287.5 Million
Revenue rose 15% year over year and exceeded FactSet estimates of $283.3 million. Adjusted EPS was $0.61 versus consensus of $0.49. IPG guided to fourth-quarter revenue of $265 mil
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC